Tech Company Financing Transactions
Favrille Funding Round
On 4/6/2004, Favrille secured $44 million in Series C funding from Alloy Ventures, De Novo Ventures and Forward Ventures.
Transaction Overview
Company Name
Announced On
4/6/2004
Transaction Type
Venture Equity
Amount
$44,000,000
Round
Series C
Proceeds Purpose
Favrille intends to use the funding to continue evaluation of ongoing Phase II clinical trials and initiate a "pivotal" Phase III clinical trial evaluating the Company's lead product candidate, FavId", as well as for general corporate purposes.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
10445 Pacific Center Court
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company, is focused on the research, development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Longenecker
Chief Financial Officer
Tamara Seymour
Chief Medical Officer
Richard Ghalie
Chief Scientific Officer
Daniel Gold
Vice President
John Bender
VP - Operations
Richard Murawski
VP - Regulatory Affairs
Alice Wei
Browse more venture capital transactions:
Prev: 4/6/2004: Staccato Communications venture capital transaction
Next: 4/6/2004: Ablynx venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We record all VC transactions involving tech companies. VC investment data records reported here are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs